The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.

The aim of this study is to explore the clinical effect of tegafur gimeracil oteracil combined with pirarubicin hydrochloride (THP) and diamminedichloroplatinum (DDP) for second-line treatment of advanced cardiac carcinoma, and find the most effective method to improve its survival rate and decrease the adverse reactions. 70 patients with advanced cardiac carcinoma admitted during February 2010-March 2014 were selected and divided into two groups with 35 cases in each group. All patients were treated with THP and DDP, and tegafur gimeracil oteracil was added to the observation group. The differences of effective rate, life quality, and adverse reactions after treatment in observational group were observed. The result of total curative effect indicated that the occurrence rate of complete remission + partial remission (CR + PR) in the control group was 28.57 %, the total effective rate was 51.43 %, the occurrence rate of CR + PR in the observational group was 34.29 %, and the total effective rate was 57.15 %; there was no statistical difference between the two groups (P > 0.05). The result of KPS scoring indicated that the improvement rate in the control group was 28.57 %, the total effective rate was 62.86 %, the improvement rate in the observational group was 42.86 %, and the total effective rate was 80 %; there was statistical difference between two groups (P < 0.05); the occurrence rates of adverse reactions including leukocyte decrease, thrombocytopenia, anemia, nausea and vomiting, constipation, peripheral neurovirulence, hepatotoxicity, and renal toxicity were statistically different (P < 0.05). Tegafur gimeracil oteracil combined with THP and DDP in treating advanced cardiac carcinoma can improve the life quality and decrease the adverse reactions.